8-K: Plus Therapeutics Advances CNS Cancer Therapies

Plus Therapeutics provides a corporate update highlighting significant progress in its CNSide diagnostic and REYOBIQ radiotherapeutic platforms, including positive clinical trial data and commercial expansion plans.

Summary

• Plus Therapeutics (PSTV) is developing CNSide, a best-in-class diagnostic for Central Nervous System (CNS) Metastases, with a Total Addressable Market (TAM) exceeding $6 billion.
• CNSide is projected to serve 500,000 patients per year and is undergoing a U.S. commercial relaunch in Q3 2025, having secured national coverage agreements with UnitedHealthcare and Humana, covering 67 million lives.
• The company's first-in-class radiotherapeutic, REYOBIQ, targets CNS cancers with a TAM over $16 billion, offering up to 20 times more radiation delivery than standard of care and holding FDA Fast Track and Orphan Designations.
• ReSPECT-LM Phase 1 trial for leptomeningeal metastases demonstrated a median overall survival (mOS) of 9 months, compared to 4-6 months for standard of care, with 93% circulating tumor cell response.
• ReSPECT-GBM Phase 1 trial for recurrent glioblastoma showed patients receiving therapeutic doses (>100 Gy) achieved 17 months mOS, significantly higher than the 8 months for standard of care, representing a 113% improvement.
• A Phase 2 ReSPECT-GBM trial is completing in 2025, with interim data showing a 63% improvement in survival for treated patients compared to real-world control arms.
• The ReSPECT-PBC Phase 1 trial for pediatric brain cancer, funded by a $3.0 million U.S. Department of Defense award, received FDA IND clearance in Q2 2025 and is expected to begin enrollment in Q1 2026.
• Key 2026 milestones include expanding CNSide covered lives to over 150 million, obtaining Medicare and Medicaid coverage, completing ReSPECT-GBM Phase 2 enrollment, and initiating ReSPECT-LM Phase 2 expansion and ReSPECT-PBC Phase 1 enrollment.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for REYOBIQ across multiple indications, showing significant improvements in median overall survival compared to standard of care. The commercial relaunch of CNSide with national coverage agreements also indicates substantial progress on the diagnostic front. The FDA designations and grant funding further bolster confidence in the company's trajectory, despite the inherent risks of biotech development.

Positives

• CNSide, a best-in-class diagnostic for CNS Mets, has a projected Total Addressable Market (TAM) of over $6 billion and is relaunching commercially in Q3 2025.
• CNSide has secured initial national coverage agreements with UnitedHealthcare and Humana, collectively covering 67 million lives, and was previously ordered by 120 U.S. institutions.
• REYOBIQ, a first-in-class radiotherapeutic for CNS Cancers, has a TAM exceeding $16 billion and delivers up to 20 times more radiation than standard of care.
• REYOBIQ has received FDA Fast Track and Orphan Designations, which can expedite the approval process.
• The ReSPECT-LM Phase 1 trial showed a median overall survival (mOS) of 9 months, a significant improvement over the 4-6 months reported for standard of care, with 4 patients remaining alive for over a year.
• ReSPECT-LM Phase 1 demonstrated a 93% circulating tumor cell (CTC) response, 76% MRI imaging response, and 87% clinical response.
• The ReSPECT-GBM Phase 1 trial reported a mOS of 17 months for patients receiving therapeutic radiation doses (>100 Gy), compared to 8 months for standard of care, representing a 113% improvement.
• Interim data from the ReSPECT-GBM Phase 2 trial indicates a 63% improvement in survival for treated patients compared to real-world control arms.
• The ReSPECT-PBC pediatric brain cancer trial is funded by a $3.0 million award from the U.S. Department of Defense, indicating external validation and support.
• Manufacturing scale-up for REYOBIQ commercial and approval trial supply is expected to be completed in 2026, supporting future commercialization.

Negatives

• The current standard for leptomeningeal metastases (LM) diagnosis (cytology from 1904) is poor, with only ~50% sensitivity, leading to 2-4 times underdiagnosis of LM cases.
• CNS cancer survival rates have shown little progress over 40 years, with a 4-decade-old playbook proving ineffective.
• Poor survival rates for LM patients, with 4-6 weeks without treatment and 4-6 months with treatment, highlight the urgent unmet medical need.
• Recurrent glioblastoma (rGBM) is an aggressive and deadly disease, with a poor 7% 5-year survival rate and almost all cases recurring, indicating a large unmet medical need.

Risks

• The product candidates and therapies are in early stages of development.
• Uncertainties exist regarding the results of research and development activities, including clinical trials.
• The company's liquidity and capital resources, and its ability to raise additional cash on acceptable terms, are uncertain.
• The outcome of partnering/licensing efforts is not guaranteed.
• Risks are associated with compliance with Nasdaq Capital Market listing requirements.
• Market conditions, product performance, and potential litigation could negatively impact the business.
• Competition within the cancer diagnostics and therapeutics field is a significant factor.
• The ability to develop and protect proprietary intellectual property or obtain licenses on commercially reasonable terms is crucial.
• Manufacturing supply chain risks could affect product availability.
• Material security breaches or cybersecurity attacks could impact operations or property.

Future Outlook

The company anticipates significant progress in 2026, including completing enrollment in the ReSPECT-GBM Phase 2 trial and conducting an end-of-phase meeting to align on pivotal trial design. For ReSPECT-LM, the optimal dose and interval will be defined for Phase 2 expansion, with enrollment commencing. Manufacturing scale-up for REYOBIQ's commercial and approval trial supply is also a key objective. On the diagnostic front, CNSide aims to reach over 150 million covered lives, secure Medicare and Medicaid coverage, establish a base of 50 or more unique ordering physicians, and expand its platform with additional CSF characterization tests. The first patient in the ReSPECT-PBC pediatric brain cancer Phase 1 trial is expected to be enrolled in Q1 2026.

Management Comments

• Management believes Plus Therapeutics is creating a new playbook to improve CNS cancer survival through improved diagnostics (CNSide) and targeted therapeutics (REYOBIQ).
• The company aims to double survival in leptomeningeal metastases (LM) through its integrated CNS platform.
• Management emphasizes the potential of REYOBIQ to safely and effectively deliver radiation directly to the tumor at high doses, bypassing the blood-brain barrier.
• The executive team is focused on leveraging the clinically proven CNSide platform for a successful commercial relaunch and scale-up.

Industry Context

The CNS cancer landscape is characterized by a growing epidemic of metastases, with over 1 million patients at risk in the U.S., largely due to improved outcomes for primary cancers. Despite this, CNS cancer survival rates have seen little progress over the past four decades, primarily due to the unique challenges of the CNS, including poor diagnostic options (e.g., 1904 cytology for LM), limited drug penetration across the blood-brain barrier, and the infiltrative nature of tumors like glioblastoma. Plus Therapeutics' strategy directly addresses these unmet needs by offering a highly sensitive diagnostic (CNSide) and a targeted radiotherapeutic (REYOBIQ) designed to overcome these inherent limitations, positioning the company as a potential leader in a field with significant therapeutic nihilism.

Comparison to Industry Standards

• For leptomeningeal metastases (LM), REYOBIQ's Phase 1 trial demonstrated a median overall survival (mOS) of 9 months, which is a substantial improvement compared to the reported standard of care (SOC) mOS of 4-6 months.
• In recurrent glioblastoma (rGBM), patients receiving therapeutic doses of REYOBIQ (>100 Gy) in the Phase 1 trial achieved an mOS of 17 months, significantly outperforming the SOC mOS of 8 months, representing a 113% improvement.
• REYOBIQ's ability to deliver up to 20 times more radiation directly to the tumor compared to external beam radiation therapy (EBRT) (e.g., ~740 Gy vs. ~30 Gy maximum dose) represents a significant advancement in precision and dosage.
• CNSide's clinical sensitivity of 92% and specificity of 95% for LM diagnosis significantly surpasses the ~50% sensitivity of traditional cytology and ~75% specificity of imaging, which are the current standard diagnostic tools.

Stakeholder Impact

• **Shareholders:** Potential for increased shareholder value due to positive clinical trial results, FDA designations, and commercial expansion of CNSide, indicating progress towards market approval and revenue generation.
• **Patients:** Significant potential for improved treatment outcomes and survival rates for patients suffering from aggressive CNS cancers like leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers, where current options are limited.
• **Healthcare Providers:** Access to a best-in-class diagnostic (CNSide) for more accurate and earlier detection of CNS metastases, and a first-in-class targeted radiotherapeutic (REYOBIQ) offering a new, more effective treatment modality for challenging CNS cancers.
• **Regulatory Authorities:** The FDA Fast Track and Orphan Designations for REYOBIQ highlight the recognized unmet medical need and the potential for these therapies to address critical gaps in cancer treatment.

Next Steps

• Complete enrollment in the ReSPECT-GBM Phase 2 diagnostic platform trial and conduct an end-of-phase meeting to align on pivotal trial design.
• Define the optimal dose/interval for REYOBIQ in the ReSPECT-LM Phase 2 expansion trial and begin enrollment.
• Complete manufacturing scale-up for REYOBIQ commercial and approval trial supply.
• Enroll the first patient in the ReSPECT-PBC pediatric brain cancer Phase 1 trial with REYOBIQ.
• Reach over 150 million covered lives for CNSide.
• Obtain Medicare and Medicaid coverage for CNSide.
• Establish a prior commercial order rate of 1,250 TCE tests per annum for CNSide.
• Establish a customer base of 50 or more unique ordering physicians for CNSide.
• Expand the CNSide platform and launch additional CSF tumor characterization tests.

Key Dates

Recommendation

The filing presents compelling clinical data for REYOBIQ, demonstrating significant improvements in median overall survival for both leptomeningeal metastases and recurrent glioblastoma patients compared to the standard of care. These are aggressive cancers with high unmet medical needs. The commercial relaunch of CNSide, coupled with securing national coverage agreements, provides a clear path to market for the diagnostic platform. FDA Fast Track and Orphan Designations further de-risk the therapeutic development. While biotech investments carry inherent risks, the strong clinical efficacy, strategic commercialization efforts, and addressing critical unmet needs position Plus Therapeutics for substantial growth and make it an attractive 'buy' for investors with a long-term horizon in the oncology space.

Keywords

Plus Therapeutics, PSTV, CNSide, REYOBIQ, Central Nervous System Cancers, Leptomeningeal Metastases, Glioblastoma, Pediatric Brain Cancer, Radiotherapeutics, Diagnostics, Clinical Trials, FDA Fast Track, Orphan Designation, SEC Filing, 8-K